London Co. of Virginia Has $11.01 Million Position in Certara, Inc. $CERT

London Co. of Virginia lowered its holdings in Certara, Inc. (NASDAQ:CERT) by 19.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,249,237 shares of the company’s stock after selling 305,754 shares during the quarter. London Co. of Virginia’s holdings in Certara were worth $11,006,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Granahan Investment Management LLC grew its position in Certara by 8.2% in the 4th quarter. Granahan Investment Management LLC now owns 460,797 shares of the company’s stock valued at $4,060,000 after purchasing an additional 34,798 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Certara in the 4th quarter valued at $113,000. Squarepoint Ops LLC grew its position in Certara by 75.3% in the 4th quarter. Squarepoint Ops LLC now owns 78,546 shares of the company’s stock valued at $692,000 after purchasing an additional 33,730 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in Certara in the 4th quarter valued at $193,000. Finally, Dixon Mitchell Investment Counsel Inc. grew its position in Certara by 78.5% in the 4th quarter. Dixon Mitchell Investment Counsel Inc. now owns 1,546,299 shares of the company’s stock valued at $13,623,000 after purchasing an additional 679,919 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Robert W. Baird reduced their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, May 12th. Craig Hallum dropped their price objective on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. BMO Capital Markets dropped their price objective on Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. Barclays dropped their price objective on Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, Morgan Stanley dropped their price objective on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Certara has an average rating of “Hold” and an average price target of $8.85.

Certara Trading Up 16.1%

NASDAQ CERT opened at $6.05 on Wednesday. The stock has a market capitalization of $941.20 million, a price-to-earnings ratio of -60.50 and a beta of 1.49. Certara, Inc. has a one year low of $4.45 and a one year high of $13.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The business’s fifty day moving average is $5.59 and its 200-day moving average is $7.12.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The business had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The company’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Equities research analysts predict that Certara, Inc. will post 0.24 EPS for the current year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.